Dear Ms. Gerry:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 16, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for INTELENCE (etravirine) 25 mg, 100 mg, 200 mg tablets.

This Prior Approval supplemental new drug application proposes the following changes:

- To expand the patient population to include treatment of HIV-1 infection in patients 2 years to less than 6 years of age weighing at least 10 kg based upon the data from Study TMC125-C234.
- The INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS, USE IN SPECIFIC POPULATIONS, CLINICAL PHARMACOLOGY, and CLINICAL STUDIES sections of the Prescribing Information were updated with pediatric related information.
- To update the PATIENT COUNSELING INFORMATION section of the Prescribing Information
- To update the Patient Information to be consistent with the Prescribing Information

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at Reference ID: 4291140
CONTENT OF LABELING MUST BE IDENTICAL TO THE ENCLOSED LABELING (TEXT FOR THE PRESCRIBING INFORMATION, AND TEXT FOR THE PATIENT PACKAGE INSERT,), WITH THE ADDITION OF ANY LABELING CHANGES IN PENDING “CHANGES BEING EFFECTED” (CBE) SUPPLEMENTS, AS WELL AS ANNUAL REPORTABLE CHANGES NOT INCLUDED IN THE ENCLOSED LABELING.

INFORMATION ON SUBMITTING SPL FILES USING ELIST MAY BE FOUND IN THE GUIDANCE FOR INDUSTRY TITLED “SPL STANDARD FOR CONTENT OF LABELING TECHNICAL QS AND AS” AT HTTP://WWW.FDA.GOV/DOWNLOADS/DRUGSGUIDANCECOMPLIANCEREGULATORYINFORMATION/GUIDANCES/UCM072392.PDF.

THE SPL WILL BE ACCESSIBLE FROM PUBLICLY AVAILABLE LABELING REPOSITORIES.

ALSO WITHIN 14 DAYS, AMEND ALL PENDING SUPPLEMENTAL APPLICATIONS THAT INCLUDE LABELING CHANGES FOR THIS NDA, INCLUDING CBE SUPPLEMENTS FOR WHICH FDA HAS NOT YET ISSUED AN ACTION LETTER, WITH THE CONTENT OF LABELING [21 CFR 314.50(l)(1)(i)] IN MS WORD FORMAT, THAT INCLUDES THE CHANGES APPROVED IN THIS SUPPLEMENTAL APPLICATION, AS WELL AS ANNUAL REPORTABLE CHANGES AND ANNOTATE EACH CHANGE. TO FACILITATE REVIEW OF YOUR SUBMISSION, PROVIDE A HIGHLIGHTED OR MARKED-UP COPY THAT SHOWS ALL CHANGES, AS WELL AS A CLEAN MICROSOFT WORD VERSION. THE MARKED-UP COPY SHOULD PROVIDE APPROPRIATE ANNOTATIONS, INCLUDING SUPPLEMENT NUMBER(S) AND ANNUAL REPORT DATE(S).

REQUIRED PEDIATRIC ASSESSMENTS

UNDER THE PEDIATRIC RESEARCH EQUITY ACT (PREA) (21 U.S.C. 355c), ALL APPLICATIONS FOR NEW ACTIVE INGREDIENTS (WHICH INCLUDES NEW SALTS AND NEW FIXED COMBINATIONS), NEW INDICATIONS, NEW DOSAGE FORMS, NEW DOSING REGIMENS, OR NEW ROUTES OF ADMINISTRATION ARE REQUIRED TO CONTAIN AN ASSESSMENT OF THE SAFETY AND EFFECTIVENESS OF THE PRODUCT FOR THE CLAIMED INDICATION IN PEDIATRIC PATIENTS UNLESS THIS REQUIREMENT IS WAIVED, DEFERRED, OR INAPPLICABLE.

WE NOTE THAT YOU HAVE FULFILLED THE PEDIATRIC STUDY REQUIREMENT FOR AGES 2 YEARS TO 6 YEARS FOR THIS APPLICATION.

FULFILLMENT OF POSTMARKETING REQUIREMENT

WE HAVE RECEIVED YOUR SUBMISSION DATED JANUARY 16, 2018, CONTAINING THE FINAL REPORT FOR THE FOLLOWING POSTMARKETING REQUIREMENT LISTED IN THE JUNE 19, 2015 POST APPROVAL POSTMARKETING REQUIREMENT LETTER.

DEFERRED PEDIATRIC STUDY UNDER PREA FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC SUBJECTS FROM 2 YEARS TO 6 YEARS OF AGE. THIS STUDY WILL DETERMINE THE PHARMACOKINETIC PROFILE, SAFETY, AND ACTIVITY OF ETRAVIRINE IN PEDIATRIC SUBJECTS FROM 2 YEARS TO 6 YEARS OF AGE.

WE HAVE REVIEWED YOUR SUBMISSION AND CONCLUDE THAT THE ABOVE REQUIREMENT WAS FULFILLED.
This completes your postmarketing requirement acknowledged in our June 19, 2015 letter.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the prescribing information to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:  

You must submit final promotional materials and prescribing information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at  
[http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf). Information and Instructions for completing the form can be found at  
[http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf). For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see  
[http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Christine Kim, PharmD, Regulatory Project Manager, at (301) 796-5964 or at the mainline at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DEBRA B BIRNKRANT
07/16/2018